130 related articles for article (PubMed ID: 15336545)
21. Methionine inhibits cellular growth dependent on the p53 status of cells.
Benavides MA; Oelschlager DK; Zhang HG; Stockard CR; Vital-Reyes VS; Katkoori VR; Manne U; Wang W; Bland KI; Grizzle WE
Am J Surg; 2007 Feb; 193(2):274-83. PubMed ID: 17236862
[TBL] [Abstract][Full Text] [Related]
22. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism.
Sainz RM; Mayo JC; Tan DX; León J; Manchester L; Reiter RJ
Prostate; 2005 Apr; 63(1):29-43. PubMed ID: 15378522
[TBL] [Abstract][Full Text] [Related]
23. RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness.
Zhang M; Altuwaijri S; Yeh S
Oncogene; 2004 Apr; 23(17):3080-8. PubMed ID: 15048090
[TBL] [Abstract][Full Text] [Related]
24. Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy.
Xu XF; Zhou SW; Zhang X; Ye ZQ; Zhang JH; Ma X; Zheng T; Li HZ
Asian J Androl; 2006 Jul; 8(4):455-62. PubMed ID: 16763722
[TBL] [Abstract][Full Text] [Related]
25. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo.
Ouafik L; Sauze S; Boudouresque F; Chinot O; Delfino C; Fina F; Vuaroqueaux V; Dussert C; Palmari J; Dufour H; Grisoli F; Casellas P; Brünner N; Martin PM
Am J Pathol; 2002 Apr; 160(4):1279-92. PubMed ID: 11943713
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
28. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells.
Yang X; Chen MW; Terry S; Vacherot F; Chopin DK; Bemis DL; Kitajewski J; Benson MC; Guo Y; Buttyan R
Cancer Res; 2005 Jun; 65(12):5263-71. PubMed ID: 15958572
[TBL] [Abstract][Full Text] [Related]
29. The sensitivity to beta-carotene growth-inhibitory and proapoptotic effects is regulated by caveolin-1 expression in human colon and prostate cancer cells.
Palozza P; Sestito R; Picci N; Lanza P; Monego G; Ranelletti FO
Carcinogenesis; 2008 Nov; 29(11):2153-61. PubMed ID: 18635524
[TBL] [Abstract][Full Text] [Related]
30. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
Guo Y; Wang S; Hoot DR; Clinton SK
J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of adrenomedullin gene markedly inhibits proliferation of PC3 prostate cancer cells in vitro and in vivo.
Abasolo I; Yang L; Haleem R; Xiao W; Pio R; Cuttitta F; Montuenga LM; Kozlowski JM; Calvo A; Wang Z
Mol Cell Endocrinol; 2003 Jan; 199(1-2):179-87. PubMed ID: 12581889
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).
Ling MT; Lau TC; Zhou C; Chua CW; Kwok WK; Wang Q; Wang X; Wong YC
Carcinogenesis; 2005 Oct; 26(10):1668-76. PubMed ID: 15905202
[TBL] [Abstract][Full Text] [Related]
34. Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer.
Wu C; Zhang L; Bourne PA; Reeder JE; di Sant'Agnese PA; Yao JL; Na Y; Huang J
Prostate; 2006 Aug; 66(11):1125-35. PubMed ID: 16652382
[TBL] [Abstract][Full Text] [Related]
35. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
Wang Y; Shao C; Shi CH; Zhang L; Yue HH; Wang PF; Yang B; Zhang YT; Liu F; Qin WJ; Wang H; Shao GX
Asian J Androl; 2005 Dec; 7(4):375-80. PubMed ID: 16281084
[TBL] [Abstract][Full Text] [Related]
36. Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines.
Dizeyi N; Bjartell A; Hedlund P; Taskén KA; Gadaleanu V; Abrahamsson PA
Eur Urol; 2005 Jun; 47(6):895-900. PubMed ID: 15925089
[TBL] [Abstract][Full Text] [Related]
37. Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase.
Singh SV; Choi S; Zeng Y; Hahm ER; Xiao D
Cancer Res; 2007 Aug; 67(15):7439-49. PubMed ID: 17671214
[TBL] [Abstract][Full Text] [Related]
38. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
Wang P; Ma Q; Luo J; Liu B; Tan F; Zhang Z; Chen Z
Cancer Invest; 2009 May; 27(4):369-75. PubMed ID: 19266349
[TBL] [Abstract][Full Text] [Related]
39. IL-6 and PPARgamma signalling in human PC-3 prostate cancer cells.
Pitulis N; Papageorgiou E; Tenta R; Lembessis P; Koutsilieris M
Anticancer Res; 2009 Jun; 29(6):2331-7. PubMed ID: 19528499
[TBL] [Abstract][Full Text] [Related]
40. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
